A Phase 1, Open-Label, Single Dose, Parallel-Group Study to Evaluate the Pharmacokinetics, Safety and Tolerability of MEDI0382 in Subjects With Renal Impairment

Trial Profile

A Phase 1, Open-Label, Single Dose, Parallel-Group Study to Evaluate the Pharmacokinetics, Safety and Tolerability of MEDI0382 in Subjects With Renal Impairment

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2017

At a glance

  • Drugs MEDI 0382 (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors MedImmune
  • Most Recent Events

    • 30 Oct 2017 Planned number of patients changed from 24 to 40.
    • 30 Oct 2017 Planned End Date changed from 28 Feb 2018 to 23 Mar 2018.
    • 30 Oct 2017 Planned primary completion date changed from 28 Feb 2018 to 23 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top